In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

✍ Scribed by Steven J. McClue; David Blake; Rosemary Clarke; Angela Cowan; Lorna Cummings; Peter M. Fischer; Mairi MacKenzie; Jean Melville; Kevin Stewart; Shudong Wang; Nikolai Zhelev; Daniella Zheleva; David P. Lane

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: French
• Weight: 112 KB
• Volume: 102
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.10738

✦ Synopsis

Abstract

CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (R‐roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC~50~ = 0.10 μM) with an average cytotoxic IC~50~ of 15.2 μM in a panel of 19 human tumour cell lines, and we also demonstrate selectivity for rapidly proliferating cells over non‐proliferating cells. A study of the cell cycle effects of CYC202 in Lovo colorectal carcinoma cells showed that the major effect was not the predicted arrest in one part of the cycle, but rather an induction of cell death from all compartments of the cell cycle. The maximum tolerated dose given intravenously to mice was in excess of 20 mg/kg. Doses up to 2,000 mg/kg were tolerated when administered orally in mice. Following repeated intraperitoneal administration (3 times daily for 5 days) of 100 mg/kg to nude mice bearing the Lovo human colorectal tumour, CYC202 induced a significant antitumour effect with a 45% reduction in tumour growth compared to controls. A second experiment using the human uterine xenograft MESSA‐DX5 treated with orally administered CYC202 (500 mg/kg 3 times daily for 4 days) also exhibited a significant reduction in the rate of growth of the tumour (62%). These data, showing enzyme and cellular potency together with antitumour activity, confirm the potential of CDK2 inhibitors such as CYC202 as anticancer drugs. © 2002 Wiley‐Liss, Inc.